Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ROADMAP project launches its Data Cube. The Cube offers a dynamic overview of the ‘landscape’ of data availability in Europe for Alzheimer’s disease research.

Funded through the Innovative Medicines Initiative, the public-private Real world outcomes across the Alzheimer's Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project brought together 26 organisations led by Novartis and coordinated by the University of Oxford.

One of the partnership's main aspirations was to support the identification and integration of realworld data across multiple sources and countries. Through that, it intended to support opportunities for the development of evidence for the reimbursement and access of new technologies for the treatment of Alzheimer's disease (AD), ultimately aiming to drive healthcare systems towards better care and data capture.

The consortium therefore collaboratively developed this 3D 'heat map' assessment. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data
sources and the intrinsic gaps, has proven to be a powerful tool for the design, planning and validation of the models and strategies used to guide future recommendations to enhance AD research.

Through these efforts, ROADMAP helps address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. The online version of the Data Cube is available here: https://datacube.roadmap-alzheimer.org.

The Data Cube is an important outcome of the ROADMAP project as it provides a much needed, overarching picture of priority outcomes, across the disease stages, and whether data is available. It helps to identify gaps in the evidence and provides a useful tool for regulatory and HTA purposes. - Dr Jacoline Bouvy, Senior Scientific Adviser, NICE

Similar stories

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Community play packs inspire families to be more playful at home

A project led by Alex Hendry working with Oxford Brookes has engaged with parents and early years practitioners in a bid to help families spend more time playing with their children.

Life and Mind Building construction tops out

Another milestone was reached this week with the topping out ceremony of the new Life and Mind Building.

Major trials to test effectiveness of cannabidiol on psychosis

Global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.